dc.contributor.author | Karlsson, Ann Tarja | |
dc.contributor.author | Vederhus, John-Kåre | |
dc.contributor.author | Clausen, Thomas | |
dc.contributor.author | Weimand, Bente | |
dc.contributor.author | Solli, Kristin Klemmetsby | |
dc.contributor.author | Tanum, Lars Håkon Reiestad | |
dc.date.accessioned | 2021-11-03T14:36:58Z | |
dc.date.available | 2021-11-03T14:36:58Z | |
dc.date.created | 2021-10-14T16:24:35Z | |
dc.date.issued | 2021-09-30 | |
dc.identifier.citation | Journal of Clinical Medicine. 2021, 10 (19), 1-9. | en_US |
dc.identifier.issn | 2077-0383 | |
dc.identifier.uri | https://hdl.handle.net/11250/2827682 | |
dc.description.abstract | The level of impulsivity, hyperactivity, and inattention (IHI) is higher among patients with substance use disorder (SUD) than in the general population. However, the prevalence of such symptoms in patients seeking treatment with an opioid antagonist, such as extended-release naltrexone (XR-NTX), is unknown. We screened 162 patients with opioid use disorder (OUD) seeking treatment with XR-NTX in Norway using the Adult ADHD Self-Report Scale (ASRS) to estimate the prevalence of IHI alongside an assessment of mental and physical health and substance use. Sixty-six patients scored above the clinical cut-off on the ASRS. Higher levels of IHI were significantly associated with a longer history of frequent amphetamine use, current alcohol use, and greater mental distress. Mental distress was the strongest factor associated with higher levels of IHI. The introduction of screening for IHI and mental distress in opioid maintenance treatment and XR-NTX would likely improve the quality of care and enable clinicians to tailor interventions to the needs of patients with high levels of IHI to prevent treatment discontinuation. | en_US |
dc.description.sponsorship | The study was supported by unrestricted grants from the Research Council of Norway (grant 269864) and the South-Eastern Norway Regional Health Authority (2019105). | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.relation.ispartofseries | Journal of Clinical Medicine;Volume 10 / Issue 19 | |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.subject | Extended-release naltrexone | en_US |
dc.subject | Opioid dependence | en_US |
dc.subject | Mental distress | en_US |
dc.subject | Impulsivity | en_US |
dc.title | Levels of impulsivity, hyperactivity, and inattention and the association with mental health and substance use severity in opioid-dependent patients seeking treatment with extended-release naltrexone | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © 2021 by the authors | en_US |
dc.source.articlenumber | 4558 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | https://doi.org/10.3390/jcm10194558 | |
dc.identifier.cristin | 1946055 | |
dc.source.journal | Journal of Clinical Medicine | en_US |
dc.source.volume | 10 | en_US |
dc.source.issue | 19 | en_US |
dc.source.pagenumber | 1-9 | en_US |
dc.relation.project | Norges forskningsråd: 269864 | en_US |
dc.relation.project | Helse Sørøst: 2019105 | en_US |